Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits.
OBJECTIVE
To investigate the thrombolytic efficacy, ideal dosage and administration of native recombinant staphylokinase (r-SAK).


METHODS
Forty New Zealand rabbits were randomly assigned into the control, r-SAK low-dose, medial-dose, high dose, single bolus, allied therapy, recombinant streptokinase (r-SK) and urokinase (UK) groups. The right femoral artery thrombosis models were made by balloon injury, and 120 min after the injury, the thrombolytic agents were infused through the rabbits' parallel-ear vein.


RESULTS
(1) 2 h after balloon injury, the pulse pressures of the right femoral arteries reduced to 0 or less than 10% of that of left femoral arteries in all groups; (2) after thrombolytic therapy, the pulse pressures in some of the femoral arteries markedly enhanced to more than 50% of that of left femoral arteries; (3) the reopening rates in the r-SAK medial and high dose groups were significantly higher than that of the control. The reopening rate of the same dose native r-SAK was significant higher than that of UK and r-SK; (4) the patency score of the right femoral arteries tended to be better in the r-SAK medial and high-dose groups than that of the low-dose group, and the time to reopening in the allied therapy group tended to be shorter.


CONCLUSIONS
(1) r-SAK has a definite thrombolytic effect on the femoral artery thrombus of rabbits; (2) single bolus is an effective manner of r-SAK therapy, and r-SAK allied therapy with heparin may shorten the time to recanalization; (3) the efficacy of the same dose native r-SAK was superior to that of r-SK and UK.
Li
Chun-Jian
CJ
Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. lijay@e165.com
Huang
Jun
J
Yang
Zhi-Jian
ZJ
Cao
Ke-Jiang
KJ
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005263:Femoral Artery / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D008297:Male; D008666:Metalloendopeptidases / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D011817:Rabbits; D011897:Random Allocation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D006493:Heparin; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus